Baptista Trino, Kin N M K Ng Ying, Beaulieu Serge
Department of Physiology, Los Andes University Medical School, Mérida, Venezuela.
Clin Pharmacokinet. 2004;43(1):1-15. doi: 10.2165/00003088-200443010-00001.
The risk of excessive bodyweight gain, glucose dysregulation and hyperlipidaemia is differentially increased by conventional and atypical antipsychotic drugs. Switching or combining agents may be sufficient in some cases, but in many instances additional drug treatment will be required. This includes oral antidiabetics, insulin and agents to treat hyperlipidaemia, hypertension and platelet dysfunction, among others. Numerous pharmacokinetic and pharmacodynamic interactions with the antipsychotics are possible, although few have been tested in formal studies. After reviewing the literature, the authors provide preliminary guidelines to assist clinicians in drug selection for this complex and fragile clinical population.
传统抗精神病药物和非典型抗精神病药物导致体重过度增加、血糖失调和高脂血症的风险增加程度存在差异。在某些情况下,换药或联合用药可能就足够了,但在许多情况下还需要额外的药物治疗。这包括口服抗糖尿病药物、胰岛素以及治疗高脂血症、高血压和血小板功能障碍等的药物。抗精神病药物可能会产生众多药代动力学和药效学相互作用,尽管在正式研究中对此进行测试的较少。在查阅文献后,作者提供了初步指南,以帮助临床医生为这一复杂且脆弱的临床群体选择药物。